True Health, a Chinese medical technology company specializing in robotic puncture and ablation devices, has filed for an IPO in Hong Kong to raise funds for product development and market expansion. The company leads China's small but fast-growing puncture robot market, projected to grow from $5.9 million in 2024 to $360 million by 2032. Despite early-stage commercialization and heavy reliance on a few customers, True Health aims to leverage its innovative technology and clinical data to capture a significant niche in medical robotics. The IPO proceeds will support scaling up operations and R&D to build sustainable revenue streams in this emerging sector.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
